



Publish in the special issue on

Translational Oncology: Genesis to Prevention

Scope of the Special Issue:

Personalized medicine and targeted therapeutics are now a reality in Oncology. Rapid translations of basic experimental research “from bench-to bedside” have yielded tangible treatments for many cancers – including various solid tumors and the so-called “liquid tumors” (e.g., leukemia, lymphoma). While many early experimental investigations gave rise to seminal translational clinical trials, the scope of translational research is expanding and still evolving. With a wealth of clinical trial-based research outcomes incorporating well-developed tissue-derived genetic analyses and molecular endpoints, current translational research often leads back to the bench. At the critical intersection of translational oncology research are the interrelated fields of Carcinogenesis, and cancer prevention research. In particular, the fields of Carcinogenesis and cancer prevention research are being transformed by translational science and experimental medicine. In response to significant advances in these emerging scientific areas, the *Journal of Carcinogenesis* is bringing out a special issue focused on the topic and soliciting manuscripts for consideration for publication in this issue. The special issue is aptly titled “**Translational Oncology: Genesis to Prevention**”, and has a target date for the print edition to appear in Spring 2012. Authors are encouraged to submit original research articles, critical reviews, commentaries or opinions in the following areas:

Clinical trial-based carcinogenesis and cancer prevention research, including translational secondary endpoints of landmark clinical trials; therapeutic prevention clinical trials (chemoprevention); targeted therapeutics related to carcinogenesis or cancer prevention research; biomarkers in carcinogenesis and cancer prevention research; DNA repair pathways in carcinogenesis and prevention research; immunological investigations of carcinogenesis and cancer prevention; molecular & genetic epidemiology relevant to carcinogenesis and cancer prevention; hypothesis-driven cancer epidemiology studies; second primary cancers (including therapy-induced second malignancies and their prevention); translational studies assessing risk prediction; translational studies on risk assessment & risk reduction; translational research in nutritional epidemiology; experimental nutritional research experimental pathology; preclinical animal models; miRNAs and siRNAs for translational research technologies; molecular and cellular imaging relevant to Carcinogenesis and cancer prevention.

The special issue will be edited by experts in the field from diverse scientific disciplines:

Jason A. Zell, DO, MPH (Co-coordinating Editor; Associate Editor, Journal of Carcinogenesis)

University of California, Irvine, Irvine, CA 92697, USA jzell@uci.edu

Hamid Band, MD, PhD. University of Nebraska Medical Center, Omaha, NE USA. hband@unmc.edu

Takuji Tanaka, MD, Ph.D. Minami-Uzura, Gifu, Japan, takutt@toukaisaibou.co.jp

Anil Vachani, M.D. Abramson Research Center, Philadelphia, PA USA avachani@mail.med.upenn.edu

Argyrios Ziogas, Ph. D. University of California, Irvine, Irvine, CA, USA aziogas@uci.edu

Gopala Kovvali, P h.D. Journal of Carcinogenesis. gopala@carcinogenesis.com

Article Submission Process: Prospective authors are invited to submit their manuscript through the Journal of Carcinogenesis online manuscript submission system located at <http://www.carcinogenesis.com/>. The authors are advised to adhere to the journal manuscript policies available. . The manuscripts undergo a double blinded peer review process and quality screening according to *Journal of Carcinogenesis* acceptance policy. *Journal of Carcinogenesis* levies an article-processing charge for every accepted article. Please write to editor@carcinogenesis.com for details. **Deadline for manuscript submission: February 15, 2012;**
Publication Date: April 15, 2012.